Clinical Trial Update: Hydroxyurea and EPO in Sickle Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the combination of hydroxyurea and erythropoietin in patients with sickle cell disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Erythropoietin (erythropoietin)
• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Julia Xu | Conditions: Anemia, Sickle Cell, Sickle Cell Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-01-07